Stockscreener 앱 받기
8.78
5.02%
0.42
전일 마감가:
$8.36
열려 있는:
$8.56
하루 거래량:
1.10M
Relative Volume:
1.60
시가총액:
$384.53M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-2.8356
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
+12.56%
1개월 성능:
+19.78%
6개월 성능:
+153.76%
1년 성능:
+96.86%
1일 변동 폭
$8.45
$9.75
1주일 범위
$7.62
$9.75
52주 변동 폭
$1.78
$9.75
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.78 | 366.14M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Momentum Shift: What is the fair value of Kyverna Therapeutics Inc stock now2025 Market Overview & Smart Swing Trading Alerts - moha.gov.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley maintains Kyverna Therapeutics (KYTX) overweight recommendation - MSN
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
Kyverna Therapeutics (KYTX) Stock Analysis Report | Financials & Insights - Benzinga
Octaware Technologies Limited Added to High Probability Setup ListEvening Star Patterns & Free Navigate Market With Precision - earlytimes.in
IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
6 Companies Hanging On in Cell Therapy - BioSpace
Kyverna Therapeutics Inc Stock Analysis and ForecastInflation Impact on Stocks & Breakout Portfolio Performance - earlytimes.in
Aug Gainers: What margin trends mean for Kyverna Therapeutics Inc. stock2025 Key Lessons & Real-Time Chart Pattern Alerts - moha.gov.vn
FY2025 Earnings Estimate for KYTX Issued By HC Wainwright - MarketBeat
Trend Recap: Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Setups & Long-Term Capital Growth Strategies - BỘ NỘI VỤ
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases - TipRanks
Why Kyverna Therapeutics Inc. stock remains resilient2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
How sentiment analysis helps forecast Kyverna Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedJuly 2025 Fed Impact & Daily Stock Trend Reports - newser.com
Is Kyverna Therapeutics Inc. stock attractive for passive investorsWeekly Profit Summary & Verified Entry Point Signals - newser.com
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX) - Seeking Alpha
KYTX: KYV-101 delivers transformative results in autoimmune diseases, targeting first-to-market leadership - TradingView
KYTX: KYV101 demonstrates transformative efficacy and safety in autoimmune diseases, targeting first-to-market leadership - TradingView
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
What analysts say about Kyverna Therapeutics Inc stockVWAP Trading Strategies & Calculate Profit Targets With AI Accuracy - earlytimes.in
What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):